Skip to main content
Fig. 2 | Cardiovascular Diabetology

Fig. 2

From: A randomised, active- and placebo-controlled, three-period crossover trial to investigate short-term effects of the dipeptidyl peptidase-4 inhibitor linagliptin on macro- and microvascular endothelial function in type 2 diabetes

Fig. 2

Change from baseline after 28 days between the three treatment groups in brachial endothelial-dependent macrocirculatory function using flow-mediated vasodilation (efficacy set). a Fasting. b 2-h postprandial. *Ratio of flow-mediated vasodilation on day 28 to flow-mediated vasodilation at baseline. †n = 40 at baseline. CI confidence interval, FMD flow-mediated vasodilation

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840